FDA Guidance Documents·· 原文未提供具体时分
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry
AI 导读
FDA 官方历史目录记录；Draft guidance；发布日期：2026-01-21。请通过官方原文与附件查阅文件。
来源：FDA Guidance Documents · fda.gov